GSK at two-year low, drug firms hit on vaccine sceptic US health appointment
Portfolio Pulse from
GSK shares hit a two-year low and AstraZeneca also faced pressure after Robert F Kennedy Jr., known for anti-vaccine views, was announced as the US health secretary by President-elect Donald Trump.
November 15, 2024 | 11:00 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AstraZeneca shares came under pressure after the announcement of Robert F Kennedy Jr. as US health secretary, due to his anti-vaccine stance.
AstraZeneca, like GSK, is affected by the appointment of an anti-vaccine advocate, which could lead to regulatory challenges and impact stock prices.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
GSK shares fell to a two-year low following the announcement of Robert F Kennedy Jr., known for anti-vaccine views, as US health secretary.
The appointment of an anti-vaccine advocate as US health secretary could negatively impact vaccine-related companies like GSK, leading to a drop in stock prices.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80